- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Evaluate safety in proposed study: CDSCO Panel tells Syngene on Suplatast Tosilate Capsule
![Evaluate safety in proposed study: CDSCO Panel tells Syngene on Suplatast Tosilate Capsule Evaluate safety in proposed study: CDSCO Panel tells Syngene on Suplatast Tosilate Capsule](https://medicaldialogues.in/h-upload/2023/03/26/750x450_206101-syngene-new.webp)
New Delhi: Approving the proposal presented by Syngene International to conduct a Phase II clinical trial of Suplatast Tosilate 100mg Capsule, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined that the firm should also evaluate safety in the proposed study and submit a revised protocol to CDSCO.
This came after Syngene International presented justification or clarification for the Phase II clinical trial (CT) of the pulmonary drug Suplatast Tosilate before the committee.
Suplatast tosilate is a Th2 cytokine inhibitor that lowers the titer of the IgE antibody through specific inhibition of the production of IL (interleukin)-4 and IL-5 by T cells and inhibits tissue infiltration by eosinophils.
Suplatast tosilate is used as an antihistamine. It has been suggested and applied in the treatment of Kimura's disease a few times.
As a new antiallergic drug, suplatast tosilate modulates T-helper type 2 cell cytokine production. Oral administration of suplatast tosilate suppressed airway hyperresponsiveness in patients with asthma by reducing eosinophilic inflammation in the airways.
At the recent SEC meeting for Pulmonary held on 21 September 2023, the expert panel reviewed the justification/clarification presented by Syngene International for the Phase II clinical trial of the pulmonary drug Suplatast Tosilate.
After detailed deliberation, the committee recommended a grant of permission to conduct the Phase II study.
In addition to the above, the committee recommended that the firm should also evaluate safety in the proposed study and submit a revised protocol to CDSCO.
Also Read:Sun Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.